Testing a Drug’s Disease-Modifying Potential For Frontotemporal Dementia
A Phase 2a clinical trial is underway to test the possible benefits of sodium selenate for people living with frontotemporal dementia. While Alzheimer’s is…
A Phase 2a clinical trial is underway to test the possible benefits of sodium selenate for people living with frontotemporal dementia. While Alzheimer’s is…
This Alzheimer’s drug has already been approved for use in China. The clinical trials that could lead to approval in the U.S. have just…
The brain’s power generators, mitochondria, could hold the key to Alzheimer’s. Despite accounting for just two percent of our body weight, the brain consumes…
Could the bacteria that causes gum disease also trigger Alzheimer’s? A drug candidate targeting this bacteria recently failed its early trials, but some experts…
Vaccines are one of the greatest medical advances in history. This strategy is now being applied to the treatment and prevention of Alzheimer’s. We…
Protollin, a new vaccine for Alzheimer’s that is administered nasally, heads to human clinical trials. Through the incredible power of our immune system, researchers…
New clinical trials on memory loss interventions are currently enrolling healthy participants with key Alzhemier’s biomarkers as young as 55 years old. Tau and…
In the future, implantable devices that interface with the brain could help people with severe neurodegenerative movement disorders communicate again through a computer or…
Researchers share insights on the infectious theory of Alzheimer’s—the idea viruses and bacteria may cause Alzheimer’s. Clinical trials are underway to test this theory….
A recent cell study shows that experimental Parkinson’s and Alzheimer’s antibodies may trigger harmful brain inflammation—which could explain clinical trials’ dismal failure rates. In…
In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
Retired neurologist Daniel Gibbs speaks about his own Alzheimer’s diagnosis, his unusual and severe case of side effects in aducanumab (Aduhelm) clinical trials, and…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
Cinical trial investigators for aducanumab (Aduhelm) discuss the significance of the drug’s recent FDA approval, the controversy surrounding its efficacy, and the uncertainty ahead….